CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...

Use of relugolix among prostate cancer patients is associated with QoL, high treatment adherence rates, and low rates of ...

Global Urology Imaging Systems Market OverviewThe global urology imaging systems market is expected to register steady growth ...

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help ...

Global Urology Devices Market OverviewThe global urology devices market is poised for steady expansion and is projected to grow at a CAGR of approximately 6–7% during the forecast period from 2024 to ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

Living with prostate cancer can be very stressful. It can affect a person’s body, life plans, relationships, and emotions. Many people don’t realize that people with prostate cancer are at risk for ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.